Global Iron Drugs

Iron Drugs Comprehensive Study by Type (Iron Dextran, Iron Sucrose, Ferric Carboxymaltose, Others), Application (Chronic Kidney Disease, Inflammatory Bowel Disease, Cancer Diseases, Others), End User (Hospital, Clinics, Others) Players and Region - Europe Market Outlook to 2030

Iron Drugs Market by XX Submarkets | Forecast Years 2024-2030  

Access Sample Report Make An Enquiry Before Purchase
  • Summary
  • Market Segments
  • Table of Content
  • List of Table & Figures
  • Players Profiled
Iron Drugs Market Scope
Iron, one of the essential elements, plays an important role in biological processes such as the synthesis of heme, energy metabolism, neurotransmitter production, formation of myoglobin, formation of collagen, and immune system function. Deficiency of iron is one of the major causes of iron deficiency anemia (IDA) associated with increased morbidity and mortality. According to a survey conducted by the Vitamin and Mineral Nutrition Information System in 2017, around 30% of anemia in women and children in developing countries is due to iron deficiency. In the 19th century, Pierre Blaud introduced ferrous sulfate which became the standard treatment for IDA. Increasing investment in the healthcare sector, and rising cases of iron deficiency anemia are aiding in the iron drugs market growth.

AttributesDetails
Study Period2018-2030
Base Year2023
UnitValue (USD Million)
Key Companies ProfiledAllergan, Inc. (United States), AMAG Pharmaceuticals, Inc. (United States), Daiichi Sankyo (Japan), Pharmacosmos (Denmark), Vifor Pharma (Switzerland), Galenica (Switzerland) and Nippon Shinyaku (Japan)
CAGR%


The companies are exploring the market by adopting mergers & acquisitions, expansions, investments, new service launches, and collaborations as their preferred strategies. The players are exploring new geographies through expansions and acquisitions to avail a competitive advantage through combined synergies. Research Analyst at AMA estimates that United Kingdom Players will contribute to the maximum growth of Europe Iron Drugs market throughout the predicted period.

Allergan, Inc. (United States), AMAG Pharmaceuticals, Inc. (United States), Daiichi Sankyo (Japan), Pharmacosmos (Denmark), Vifor Pharma (Switzerland), Galenica (Switzerland) and Nippon Shinyaku (Japan) are some of the key players that are part of study coverage. Additionally, the Players which are also part of the research are Sanofi S.A. (France), Shield Therapeutics plc (United States) and Wanbang Biopharmaceutical (China).

About Approach
The research aims to propose a patent-based approach in searching for potential technology partners as a supporting tool for enabling open innovation. The study also proposes a systematic searching process of technology partners as a preliminary step to select the emerging and key players that are involved in implementing market estimations. While patent analysis is employed to overcome the aforementioned data- and process-related limitations, as expenses occurred in that technology allows us to estimate the market size by evolving segments as target market from the total available market.

Segmentation Overview
The study have segmented the market of Europe Iron Drugs market by Type , by Application (Chronic Kidney Disease, Inflammatory Bowel Disease, Cancer Diseases and Others) and Region with country level break-up.

On the basis of geography, the market of Iron Drugs has been segmented into South America (Brazil, Argentina, Rest of South America), Asia Pacific (China, Japan, India, South Korea, Taiwan, Australia, Rest of Asia-Pacific), Europe (Germany, France, Italy, United Kingdom, Netherlands, Rest of Europe), MEA (Middle East, Africa), North America (United States, Canada, Mexico). region held largest market share in the year 2023.

Market Leaders and their expansionary development strategies

On 2nd August 2019, FDA has approved Accrufer for the treatment of iron deficiency in adults with chronic kidney disease. Accrufer (ferric maltol), manufactured by U.K.-based Shield Therapeutics plc, is an oral treatment that provides an alternative to salt-based oral iron therapies, according to a company press release. The drug is absorbed from the ferric maltol molecule and generally does not cause gastrointestinal adverse events (ie, nausea, bloating and constipation) typically observed with salt-based therapies.


Influencing Trend:
Rising Geriatric Population

Market Growth Drivers:
Growing Prevalence of Chronic Kidney Disease, increasing Number of Patients Undergoing Dialysis and Rising Investment by Governments and Private Companies in Biotechnology and Biopharmaceutical Industry

Challenges:
Stringent Regulations, Drug Side Effects, Nutraceutical Alternatives to Prevent Iron Deficiency, and Product Price

Restraints:
Complex Approval Process

Opportunities:
Increase in Iron Deficiency Anemia in Gynecology, Oncology, and Gastroenterology, Noncompliance of Oral Therapy, and Accurate, Easy, and Convenient Access to IV Iron Dosages Drive Demand for Intravenous Iron Drugs

Key Target Audience
Iron Drugs Manufacturers, Research Organizations and Consulting Companies, Potential Technology Investors, Regulatory & Government Bodies, Downstream Vendors and End Users

Report Objectives / Segmentation Covered

By Type
  • Iron Dextran
  • Iron Sucrose
  • Ferric Carboxymaltose
  • Others
By Application
  • Chronic Kidney Disease
  • Inflammatory Bowel Disease
  • Cancer Diseases
  • Others
By End User
  • Hospital
  • Clinics
  • Others

By Regions
  • South America
    • Brazil
    • Argentina
    • Rest of South America
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Taiwan
    • Australia
    • Rest of Asia-Pacific
  • Europe
    • Germany
    • France
    • Italy
    • United Kingdom
    • Netherlands
    • Rest of Europe
  • MEA
    • Middle East
    • Africa
  • North America
    • United States
    • Canada
    • Mexico
  • 1. Market Overview
    • 1.1. Introduction
    • 1.2. Scope/Objective of the Study
      • 1.2.1. Research Objective
  • 2. Executive Summary
    • 2.1. Introduction
  • 3. Market Dynamics
    • 3.1. Introduction
    • 3.2. Market Drivers
      • 3.2.1. Growing Prevalence of Chronic Kidney Disease
      • 3.2.2. Increasing Number of Patients Undergoing Dialysis
      • 3.2.3. Rising Investment by Governments and Private Companies in Biotechnology and Biopharmaceutical Industry
    • 3.3. Market Challenges
      • 3.3.1. Stringent Regulations, Drug Side Effects, Nutraceutical Alternatives to Prevent Iron Deficiency, and Product Price
    • 3.4. Market Trends
      • 3.4.1. Rising Geriatric Population
  • 4. Market Factor Analysis
    • 4.1. Porters Five Forces
    • 4.2. Supply/Value Chain
    • 4.3. PESTEL analysis
    • 4.4. Market Entropy
    • 4.5. Patent/Trademark Analysis
  • 5. Europe Iron Drugs, by Type, Application, End User and Region (value, volume and price ) (2018-2023)
    • 5.1. Introduction
    • 5.2. Europe Iron Drugs (Value)
      • 5.2.1. Europe Iron Drugs by: Type (Value)
        • 5.2.1.1. Iron Dextran
        • 5.2.1.2. Iron Sucrose
        • 5.2.1.3. Ferric Carboxymaltose
        • 5.2.1.4. Others
      • 5.2.2. Europe Iron Drugs by: Application (Value)
        • 5.2.2.1. Chronic Kidney Disease
        • 5.2.2.2. Inflammatory Bowel Disease
        • 5.2.2.3. Cancer Diseases
        • 5.2.2.4. Others
      • 5.2.3. Europe Iron Drugs by: End User (Value)
        • 5.2.3.1. Hospital
        • 5.2.3.2. Clinics
        • 5.2.3.3. Others
      • 5.2.4. Europe Iron Drugs Region
        • 5.2.4.1. South America
          • 5.2.4.1.1. Brazil
          • 5.2.4.1.2. Argentina
          • 5.2.4.1.3. Rest of South America
        • 5.2.4.2. Asia Pacific
          • 5.2.4.2.1. China
          • 5.2.4.2.2. Japan
          • 5.2.4.2.3. India
          • 5.2.4.2.4. South Korea
          • 5.2.4.2.5. Taiwan
          • 5.2.4.2.6. Australia
          • 5.2.4.2.7. Rest of Asia-Pacific
        • 5.2.4.3. Europe
          • 5.2.4.3.1. Germany
          • 5.2.4.3.2. France
          • 5.2.4.3.3. Italy
          • 5.2.4.3.4. United Kingdom
          • 5.2.4.3.5. Netherlands
          • 5.2.4.3.6. Rest of Europe
        • 5.2.4.4. MEA
          • 5.2.4.4.1. Middle East
          • 5.2.4.4.2. Africa
        • 5.2.4.5. North America
          • 5.2.4.5.1. United States
          • 5.2.4.5.2. Canada
          • 5.2.4.5.3. Mexico
    • 5.3. Europe Iron Drugs (Volume)
      • 5.3.1. Europe Iron Drugs by: Type (Volume)
        • 5.3.1.1. Iron Dextran
        • 5.3.1.2. Iron Sucrose
        • 5.3.1.3. Ferric Carboxymaltose
        • 5.3.1.4. Others
      • 5.3.2. Europe Iron Drugs by: Application (Volume)
        • 5.3.2.1. Chronic Kidney Disease
        • 5.3.2.2. Inflammatory Bowel Disease
        • 5.3.2.3. Cancer Diseases
        • 5.3.2.4. Others
      • 5.3.3. Europe Iron Drugs by: End User (Volume)
        • 5.3.3.1. Hospital
        • 5.3.3.2. Clinics
        • 5.3.3.3. Others
      • 5.3.4. Europe Iron Drugs Region
        • 5.3.4.1. South America
          • 5.3.4.1.1. Brazil
          • 5.3.4.1.2. Argentina
          • 5.3.4.1.3. Rest of South America
        • 5.3.4.2. Asia Pacific
          • 5.3.4.2.1. China
          • 5.3.4.2.2. Japan
          • 5.3.4.2.3. India
          • 5.3.4.2.4. South Korea
          • 5.3.4.2.5. Taiwan
          • 5.3.4.2.6. Australia
          • 5.3.4.2.7. Rest of Asia-Pacific
        • 5.3.4.3. Europe
          • 5.3.4.3.1. Germany
          • 5.3.4.3.2. France
          • 5.3.4.3.3. Italy
          • 5.3.4.3.4. United Kingdom
          • 5.3.4.3.5. Netherlands
          • 5.3.4.3.6. Rest of Europe
        • 5.3.4.4. MEA
          • 5.3.4.4.1. Middle East
          • 5.3.4.4.2. Africa
        • 5.3.4.5. North America
          • 5.3.4.5.1. United States
          • 5.3.4.5.2. Canada
          • 5.3.4.5.3. Mexico
    • 5.4. Europe Iron Drugs (Price)
      • 5.4.1. Europe Iron Drugs by: Type (Price)
  • 6. Iron Drugs: Manufacturers/Players Analysis
    • 6.1. Competitive Landscape
      • 6.1.1. Market Share Analysis
        • 6.1.1.1. Top 3
    • 6.2. Peer Group Analysis (2023)
    • 6.3. BCG Matrix
    • 6.4. Company Profile
      • 6.4.1. Allergan, Inc. (United States)
        • 6.4.1.1. Business Overview
        • 6.4.1.2. Products/Services Offerings
        • 6.4.1.3. Financial Analysis
        • 6.4.1.4. SWOT Analysis
      • 6.4.2. AMAG Pharmaceuticals, Inc. (United States)
        • 6.4.2.1. Business Overview
        • 6.4.2.2. Products/Services Offerings
        • 6.4.2.3. Financial Analysis
        • 6.4.2.4. SWOT Analysis
      • 6.4.3. Daiichi Sankyo (Japan)
        • 6.4.3.1. Business Overview
        • 6.4.3.2. Products/Services Offerings
        • 6.4.3.3. Financial Analysis
        • 6.4.3.4. SWOT Analysis
      • 6.4.4. Pharmacosmos (Denmark)
        • 6.4.4.1. Business Overview
        • 6.4.4.2. Products/Services Offerings
        • 6.4.4.3. Financial Analysis
        • 6.4.4.4. SWOT Analysis
      • 6.4.5. Vifor Pharma (Switzerland)
        • 6.4.5.1. Business Overview
        • 6.4.5.2. Products/Services Offerings
        • 6.4.5.3. Financial Analysis
        • 6.4.5.4. SWOT Analysis
      • 6.4.6. Galenica (Switzerland)
        • 6.4.6.1. Business Overview
        • 6.4.6.2. Products/Services Offerings
        • 6.4.6.3. Financial Analysis
        • 6.4.6.4. SWOT Analysis
      • 6.4.7. Nippon Shinyaku (Japan)
        • 6.4.7.1. Business Overview
        • 6.4.7.2. Products/Services Offerings
        • 6.4.7.3. Financial Analysis
        • 6.4.7.4. SWOT Analysis
  • 7. Europe Iron Drugs Sale, by Type, Application, End User and Region (value, volume and price ) (2025-2030)
    • 7.1. Introduction
    • 7.2. Europe Iron Drugs (Value)
      • 7.2.1. Europe Iron Drugs by: Type (Value)
        • 7.2.1.1. Iron Dextran
        • 7.2.1.2. Iron Sucrose
        • 7.2.1.3. Ferric Carboxymaltose
        • 7.2.1.4. Others
      • 7.2.2. Europe Iron Drugs by: Application (Value)
        • 7.2.2.1. Chronic Kidney Disease
        • 7.2.2.2. Inflammatory Bowel Disease
        • 7.2.2.3. Cancer Diseases
        • 7.2.2.4. Others
      • 7.2.3. Europe Iron Drugs by: End User (Value)
        • 7.2.3.1. Hospital
        • 7.2.3.2. Clinics
        • 7.2.3.3. Others
      • 7.2.4. Europe Iron Drugs Region
        • 7.2.4.1. South America
          • 7.2.4.1.1. Brazil
          • 7.2.4.1.2. Argentina
          • 7.2.4.1.3. Rest of South America
        • 7.2.4.2. Asia Pacific
          • 7.2.4.2.1. China
          • 7.2.4.2.2. Japan
          • 7.2.4.2.3. India
          • 7.2.4.2.4. South Korea
          • 7.2.4.2.5. Taiwan
          • 7.2.4.2.6. Australia
          • 7.2.4.2.7. Rest of Asia-Pacific
        • 7.2.4.3. Europe
          • 7.2.4.3.1. Germany
          • 7.2.4.3.2. France
          • 7.2.4.3.3. Italy
          • 7.2.4.3.4. United Kingdom
          • 7.2.4.3.5. Netherlands
          • 7.2.4.3.6. Rest of Europe
        • 7.2.4.4. MEA
          • 7.2.4.4.1. Middle East
          • 7.2.4.4.2. Africa
        • 7.2.4.5. North America
          • 7.2.4.5.1. United States
          • 7.2.4.5.2. Canada
          • 7.2.4.5.3. Mexico
    • 7.3. Europe Iron Drugs (Volume)
      • 7.3.1. Europe Iron Drugs by: Type (Volume)
        • 7.3.1.1. Iron Dextran
        • 7.3.1.2. Iron Sucrose
        • 7.3.1.3. Ferric Carboxymaltose
        • 7.3.1.4. Others
      • 7.3.2. Europe Iron Drugs by: Application (Volume)
        • 7.3.2.1. Chronic Kidney Disease
        • 7.3.2.2. Inflammatory Bowel Disease
        • 7.3.2.3. Cancer Diseases
        • 7.3.2.4. Others
      • 7.3.3. Europe Iron Drugs by: End User (Volume)
        • 7.3.3.1. Hospital
        • 7.3.3.2. Clinics
        • 7.3.3.3. Others
      • 7.3.4. Europe Iron Drugs Region
        • 7.3.4.1. South America
          • 7.3.4.1.1. Brazil
          • 7.3.4.1.2. Argentina
          • 7.3.4.1.3. Rest of South America
        • 7.3.4.2. Asia Pacific
          • 7.3.4.2.1. China
          • 7.3.4.2.2. Japan
          • 7.3.4.2.3. India
          • 7.3.4.2.4. South Korea
          • 7.3.4.2.5. Taiwan
          • 7.3.4.2.6. Australia
          • 7.3.4.2.7. Rest of Asia-Pacific
        • 7.3.4.3. Europe
          • 7.3.4.3.1. Germany
          • 7.3.4.3.2. France
          • 7.3.4.3.3. Italy
          • 7.3.4.3.4. United Kingdom
          • 7.3.4.3.5. Netherlands
          • 7.3.4.3.6. Rest of Europe
        • 7.3.4.4. MEA
          • 7.3.4.4.1. Middle East
          • 7.3.4.4.2. Africa
        • 7.3.4.5. North America
          • 7.3.4.5.1. United States
          • 7.3.4.5.2. Canada
          • 7.3.4.5.3. Mexico
    • 7.4. Europe Iron Drugs (Price)
      • 7.4.1. Europe Iron Drugs by: Type (Price)
  • 8. Appendix
    • 8.1. Acronyms
  • 9. Methodology and Data Source
    • 9.1. Methodology/Research Approach
      • 9.1.1. Research Programs/Design
      • 9.1.2. Market Size Estimation
      • 9.1.3. Market Breakdown and Data Triangulation
    • 9.2. Data Source
      • 9.2.1. Secondary Sources
      • 9.2.2. Primary Sources
    • 9.3. Disclaimer
List of Tables
  • Table 1. Iron Drugs: by Type(USD Million)
  • Table 2. Iron Drugs Iron Dextran , by Region USD Million (2018-2023)
  • Table 3. Iron Drugs Iron Sucrose , by Region USD Million (2018-2023)
  • Table 4. Iron Drugs Ferric Carboxymaltose , by Region USD Million (2018-2023)
  • Table 5. Iron Drugs Others , by Region USD Million (2018-2023)
  • Table 6. Iron Drugs: by Application(USD Million)
  • Table 7. Iron Drugs Chronic Kidney Disease , by Region USD Million (2018-2023)
  • Table 8. Iron Drugs Inflammatory Bowel Disease , by Region USD Million (2018-2023)
  • Table 9. Iron Drugs Cancer Diseases , by Region USD Million (2018-2023)
  • Table 10. Iron Drugs Others , by Region USD Million (2018-2023)
  • Table 11. Iron Drugs: by End User(USD Million)
  • Table 12. Iron Drugs Hospital , by Region USD Million (2018-2023)
  • Table 13. Iron Drugs Clinics , by Region USD Million (2018-2023)
  • Table 14. Iron Drugs Others , by Region USD Million (2018-2023)
  • Table 15. South America Iron Drugs, by Country USD Million (2018-2023)
  • Table 16. South America Iron Drugs, by Type USD Million (2018-2023)
  • Table 17. South America Iron Drugs, by Application USD Million (2018-2023)
  • Table 18. South America Iron Drugs, by End User USD Million (2018-2023)
  • Table 19. Brazil Iron Drugs, by Type USD Million (2018-2023)
  • Table 20. Brazil Iron Drugs, by Application USD Million (2018-2023)
  • Table 21. Brazil Iron Drugs, by End User USD Million (2018-2023)
  • Table 22. Argentina Iron Drugs, by Type USD Million (2018-2023)
  • Table 23. Argentina Iron Drugs, by Application USD Million (2018-2023)
  • Table 24. Argentina Iron Drugs, by End User USD Million (2018-2023)
  • Table 25. Rest of South America Iron Drugs, by Type USD Million (2018-2023)
  • Table 26. Rest of South America Iron Drugs, by Application USD Million (2018-2023)
  • Table 27. Rest of South America Iron Drugs, by End User USD Million (2018-2023)
  • Table 28. Asia Pacific Iron Drugs, by Country USD Million (2018-2023)
  • Table 29. Asia Pacific Iron Drugs, by Type USD Million (2018-2023)
  • Table 30. Asia Pacific Iron Drugs, by Application USD Million (2018-2023)
  • Table 31. Asia Pacific Iron Drugs, by End User USD Million (2018-2023)
  • Table 32. China Iron Drugs, by Type USD Million (2018-2023)
  • Table 33. China Iron Drugs, by Application USD Million (2018-2023)
  • Table 34. China Iron Drugs, by End User USD Million (2018-2023)
  • Table 35. Japan Iron Drugs, by Type USD Million (2018-2023)
  • Table 36. Japan Iron Drugs, by Application USD Million (2018-2023)
  • Table 37. Japan Iron Drugs, by End User USD Million (2018-2023)
  • Table 38. India Iron Drugs, by Type USD Million (2018-2023)
  • Table 39. India Iron Drugs, by Application USD Million (2018-2023)
  • Table 40. India Iron Drugs, by End User USD Million (2018-2023)
  • Table 41. South Korea Iron Drugs, by Type USD Million (2018-2023)
  • Table 42. South Korea Iron Drugs, by Application USD Million (2018-2023)
  • Table 43. South Korea Iron Drugs, by End User USD Million (2018-2023)
  • Table 44. Taiwan Iron Drugs, by Type USD Million (2018-2023)
  • Table 45. Taiwan Iron Drugs, by Application USD Million (2018-2023)
  • Table 46. Taiwan Iron Drugs, by End User USD Million (2018-2023)
  • Table 47. Australia Iron Drugs, by Type USD Million (2018-2023)
  • Table 48. Australia Iron Drugs, by Application USD Million (2018-2023)
  • Table 49. Australia Iron Drugs, by End User USD Million (2018-2023)
  • Table 50. Rest of Asia-Pacific Iron Drugs, by Type USD Million (2018-2023)
  • Table 51. Rest of Asia-Pacific Iron Drugs, by Application USD Million (2018-2023)
  • Table 52. Rest of Asia-Pacific Iron Drugs, by End User USD Million (2018-2023)
  • Table 53. Europe Iron Drugs, by Country USD Million (2018-2023)
  • Table 54. Europe Iron Drugs, by Type USD Million (2018-2023)
  • Table 55. Europe Iron Drugs, by Application USD Million (2018-2023)
  • Table 56. Europe Iron Drugs, by End User USD Million (2018-2023)
  • Table 57. Germany Iron Drugs, by Type USD Million (2018-2023)
  • Table 58. Germany Iron Drugs, by Application USD Million (2018-2023)
  • Table 59. Germany Iron Drugs, by End User USD Million (2018-2023)
  • Table 60. France Iron Drugs, by Type USD Million (2018-2023)
  • Table 61. France Iron Drugs, by Application USD Million (2018-2023)
  • Table 62. France Iron Drugs, by End User USD Million (2018-2023)
  • Table 63. Italy Iron Drugs, by Type USD Million (2018-2023)
  • Table 64. Italy Iron Drugs, by Application USD Million (2018-2023)
  • Table 65. Italy Iron Drugs, by End User USD Million (2018-2023)
  • Table 66. United Kingdom Iron Drugs, by Type USD Million (2018-2023)
  • Table 67. United Kingdom Iron Drugs, by Application USD Million (2018-2023)
  • Table 68. United Kingdom Iron Drugs, by End User USD Million (2018-2023)
  • Table 69. Netherlands Iron Drugs, by Type USD Million (2018-2023)
  • Table 70. Netherlands Iron Drugs, by Application USD Million (2018-2023)
  • Table 71. Netherlands Iron Drugs, by End User USD Million (2018-2023)
  • Table 72. Rest of Europe Iron Drugs, by Type USD Million (2018-2023)
  • Table 73. Rest of Europe Iron Drugs, by Application USD Million (2018-2023)
  • Table 74. Rest of Europe Iron Drugs, by End User USD Million (2018-2023)
  • Table 75. MEA Iron Drugs, by Country USD Million (2018-2023)
  • Table 76. MEA Iron Drugs, by Type USD Million (2018-2023)
  • Table 77. MEA Iron Drugs, by Application USD Million (2018-2023)
  • Table 78. MEA Iron Drugs, by End User USD Million (2018-2023)
  • Table 79. Middle East Iron Drugs, by Type USD Million (2018-2023)
  • Table 80. Middle East Iron Drugs, by Application USD Million (2018-2023)
  • Table 81. Middle East Iron Drugs, by End User USD Million (2018-2023)
  • Table 82. Africa Iron Drugs, by Type USD Million (2018-2023)
  • Table 83. Africa Iron Drugs, by Application USD Million (2018-2023)
  • Table 84. Africa Iron Drugs, by End User USD Million (2018-2023)
  • Table 85. North America Iron Drugs, by Country USD Million (2018-2023)
  • Table 86. North America Iron Drugs, by Type USD Million (2018-2023)
  • Table 87. North America Iron Drugs, by Application USD Million (2018-2023)
  • Table 88. North America Iron Drugs, by End User USD Million (2018-2023)
  • Table 89. United States Iron Drugs, by Type USD Million (2018-2023)
  • Table 90. United States Iron Drugs, by Application USD Million (2018-2023)
  • Table 91. United States Iron Drugs, by End User USD Million (2018-2023)
  • Table 92. Canada Iron Drugs, by Type USD Million (2018-2023)
  • Table 93. Canada Iron Drugs, by Application USD Million (2018-2023)
  • Table 94. Canada Iron Drugs, by End User USD Million (2018-2023)
  • Table 95. Mexico Iron Drugs, by Type USD Million (2018-2023)
  • Table 96. Mexico Iron Drugs, by Application USD Million (2018-2023)
  • Table 97. Mexico Iron Drugs, by End User USD Million (2018-2023)
  • Table 98. Iron Drugs Sales: by Type(K Units)
  • Table 99. Iron Drugs Sales Iron Dextran , by Region K Units (2018-2023)
  • Table 100. Iron Drugs Sales Iron Sucrose , by Region K Units (2018-2023)
  • Table 101. Iron Drugs Sales Ferric Carboxymaltose , by Region K Units (2018-2023)
  • Table 102. Iron Drugs Sales Others , by Region K Units (2018-2023)
  • Table 103. Iron Drugs Sales: by Application(K Units)
  • Table 104. Iron Drugs Sales Chronic Kidney Disease , by Region K Units (2018-2023)
  • Table 105. Iron Drugs Sales Inflammatory Bowel Disease , by Region K Units (2018-2023)
  • Table 106. Iron Drugs Sales Cancer Diseases , by Region K Units (2018-2023)
  • Table 107. Iron Drugs Sales Others , by Region K Units (2018-2023)
  • Table 108. Iron Drugs Sales: by End User(K Units)
  • Table 109. Iron Drugs Sales Hospital , by Region K Units (2018-2023)
  • Table 110. Iron Drugs Sales Clinics , by Region K Units (2018-2023)
  • Table 111. Iron Drugs Sales Others , by Region K Units (2018-2023)
  • Table 112. South America Iron Drugs Sales, by Country K Units (2018-2023)
  • Table 113. South America Iron Drugs Sales, by Type K Units (2018-2023)
  • Table 114. South America Iron Drugs Sales, by Application K Units (2018-2023)
  • Table 115. South America Iron Drugs Sales, by End User K Units (2018-2023)
  • Table 116. Brazil Iron Drugs Sales, by Type K Units (2018-2023)
  • Table 117. Brazil Iron Drugs Sales, by Application K Units (2018-2023)
  • Table 118. Brazil Iron Drugs Sales, by End User K Units (2018-2023)
  • Table 119. Argentina Iron Drugs Sales, by Type K Units (2018-2023)
  • Table 120. Argentina Iron Drugs Sales, by Application K Units (2018-2023)
  • Table 121. Argentina Iron Drugs Sales, by End User K Units (2018-2023)
  • Table 122. Rest of South America Iron Drugs Sales, by Type K Units (2018-2023)
  • Table 123. Rest of South America Iron Drugs Sales, by Application K Units (2018-2023)
  • Table 124. Rest of South America Iron Drugs Sales, by End User K Units (2018-2023)
  • Table 125. Asia Pacific Iron Drugs Sales, by Country K Units (2018-2023)
  • Table 126. Asia Pacific Iron Drugs Sales, by Type K Units (2018-2023)
  • Table 127. Asia Pacific Iron Drugs Sales, by Application K Units (2018-2023)
  • Table 128. Asia Pacific Iron Drugs Sales, by End User K Units (2018-2023)
  • Table 129. China Iron Drugs Sales, by Type K Units (2018-2023)
  • Table 130. China Iron Drugs Sales, by Application K Units (2018-2023)
  • Table 131. China Iron Drugs Sales, by End User K Units (2018-2023)
  • Table 132. Japan Iron Drugs Sales, by Type K Units (2018-2023)
  • Table 133. Japan Iron Drugs Sales, by Application K Units (2018-2023)
  • Table 134. Japan Iron Drugs Sales, by End User K Units (2018-2023)
  • Table 135. India Iron Drugs Sales, by Type K Units (2018-2023)
  • Table 136. India Iron Drugs Sales, by Application K Units (2018-2023)
  • Table 137. India Iron Drugs Sales, by End User K Units (2018-2023)
  • Table 138. South Korea Iron Drugs Sales, by Type K Units (2018-2023)
  • Table 139. South Korea Iron Drugs Sales, by Application K Units (2018-2023)
  • Table 140. South Korea Iron Drugs Sales, by End User K Units (2018-2023)
  • Table 141. Taiwan Iron Drugs Sales, by Type K Units (2018-2023)
  • Table 142. Taiwan Iron Drugs Sales, by Application K Units (2018-2023)
  • Table 143. Taiwan Iron Drugs Sales, by End User K Units (2018-2023)
  • Table 144. Australia Iron Drugs Sales, by Type K Units (2018-2023)
  • Table 145. Australia Iron Drugs Sales, by Application K Units (2018-2023)
  • Table 146. Australia Iron Drugs Sales, by End User K Units (2018-2023)
  • Table 147. Rest of Asia-Pacific Iron Drugs Sales, by Type K Units (2018-2023)
  • Table 148. Rest of Asia-Pacific Iron Drugs Sales, by Application K Units (2018-2023)
  • Table 149. Rest of Asia-Pacific Iron Drugs Sales, by End User K Units (2018-2023)
  • Table 150. Europe Iron Drugs Sales, by Country K Units (2018-2023)
  • Table 151. Europe Iron Drugs Sales, by Type K Units (2018-2023)
  • Table 152. Europe Iron Drugs Sales, by Application K Units (2018-2023)
  • Table 153. Europe Iron Drugs Sales, by End User K Units (2018-2023)
  • Table 154. Germany Iron Drugs Sales, by Type K Units (2018-2023)
  • Table 155. Germany Iron Drugs Sales, by Application K Units (2018-2023)
  • Table 156. Germany Iron Drugs Sales, by End User K Units (2018-2023)
  • Table 157. France Iron Drugs Sales, by Type K Units (2018-2023)
  • Table 158. France Iron Drugs Sales, by Application K Units (2018-2023)
  • Table 159. France Iron Drugs Sales, by End User K Units (2018-2023)
  • Table 160. Italy Iron Drugs Sales, by Type K Units (2018-2023)
  • Table 161. Italy Iron Drugs Sales, by Application K Units (2018-2023)
  • Table 162. Italy Iron Drugs Sales, by End User K Units (2018-2023)
  • Table 163. United Kingdom Iron Drugs Sales, by Type K Units (2018-2023)
  • Table 164. United Kingdom Iron Drugs Sales, by Application K Units (2018-2023)
  • Table 165. United Kingdom Iron Drugs Sales, by End User K Units (2018-2023)
  • Table 166. Netherlands Iron Drugs Sales, by Type K Units (2018-2023)
  • Table 167. Netherlands Iron Drugs Sales, by Application K Units (2018-2023)
  • Table 168. Netherlands Iron Drugs Sales, by End User K Units (2018-2023)
  • Table 169. Rest of Europe Iron Drugs Sales, by Type K Units (2018-2023)
  • Table 170. Rest of Europe Iron Drugs Sales, by Application K Units (2018-2023)
  • Table 171. Rest of Europe Iron Drugs Sales, by End User K Units (2018-2023)
  • Table 172. MEA Iron Drugs Sales, by Country K Units (2018-2023)
  • Table 173. MEA Iron Drugs Sales, by Type K Units (2018-2023)
  • Table 174. MEA Iron Drugs Sales, by Application K Units (2018-2023)
  • Table 175. MEA Iron Drugs Sales, by End User K Units (2018-2023)
  • Table 176. Middle East Iron Drugs Sales, by Type K Units (2018-2023)
  • Table 177. Middle East Iron Drugs Sales, by Application K Units (2018-2023)
  • Table 178. Middle East Iron Drugs Sales, by End User K Units (2018-2023)
  • Table 179. Africa Iron Drugs Sales, by Type K Units (2018-2023)
  • Table 180. Africa Iron Drugs Sales, by Application K Units (2018-2023)
  • Table 181. Africa Iron Drugs Sales, by End User K Units (2018-2023)
  • Table 182. North America Iron Drugs Sales, by Country K Units (2018-2023)
  • Table 183. North America Iron Drugs Sales, by Type K Units (2018-2023)
  • Table 184. North America Iron Drugs Sales, by Application K Units (2018-2023)
  • Table 185. North America Iron Drugs Sales, by End User K Units (2018-2023)
  • Table 186. United States Iron Drugs Sales, by Type K Units (2018-2023)
  • Table 187. United States Iron Drugs Sales, by Application K Units (2018-2023)
  • Table 188. United States Iron Drugs Sales, by End User K Units (2018-2023)
  • Table 189. Canada Iron Drugs Sales, by Type K Units (2018-2023)
  • Table 190. Canada Iron Drugs Sales, by Application K Units (2018-2023)
  • Table 191. Canada Iron Drugs Sales, by End User K Units (2018-2023)
  • Table 192. Mexico Iron Drugs Sales, by Type K Units (2018-2023)
  • Table 193. Mexico Iron Drugs Sales, by Application K Units (2018-2023)
  • Table 194. Mexico Iron Drugs Sales, by End User K Units (2018-2023)
  • Table 195. Iron Drugs: by Type(USD/Units)
  • Table 196. Company Basic Information, Sales Area and Its Competitors
  • Table 197. Company Basic Information, Sales Area and Its Competitors
  • Table 198. Company Basic Information, Sales Area and Its Competitors
  • Table 199. Company Basic Information, Sales Area and Its Competitors
  • Table 200. Company Basic Information, Sales Area and Its Competitors
  • Table 201. Company Basic Information, Sales Area and Its Competitors
  • Table 202. Company Basic Information, Sales Area and Its Competitors
  • Table 203. Iron Drugs: by Type(USD Million)
  • Table 204. Iron Drugs Iron Dextran , by Region USD Million (2025-2030)
  • Table 205. Iron Drugs Iron Sucrose , by Region USD Million (2025-2030)
  • Table 206. Iron Drugs Ferric Carboxymaltose , by Region USD Million (2025-2030)
  • Table 207. Iron Drugs Others , by Region USD Million (2025-2030)
  • Table 208. Iron Drugs: by Application(USD Million)
  • Table 209. Iron Drugs Chronic Kidney Disease , by Region USD Million (2025-2030)
  • Table 210. Iron Drugs Inflammatory Bowel Disease , by Region USD Million (2025-2030)
  • Table 211. Iron Drugs Cancer Diseases , by Region USD Million (2025-2030)
  • Table 212. Iron Drugs Others , by Region USD Million (2025-2030)
  • Table 213. Iron Drugs: by End User(USD Million)
  • Table 214. Iron Drugs Hospital , by Region USD Million (2025-2030)
  • Table 215. Iron Drugs Clinics , by Region USD Million (2025-2030)
  • Table 216. Iron Drugs Others , by Region USD Million (2025-2030)
  • Table 217. South America Iron Drugs, by Country USD Million (2025-2030)
  • Table 218. South America Iron Drugs, by Type USD Million (2025-2030)
  • Table 219. South America Iron Drugs, by Application USD Million (2025-2030)
  • Table 220. South America Iron Drugs, by End User USD Million (2025-2030)
  • Table 221. Brazil Iron Drugs, by Type USD Million (2025-2030)
  • Table 222. Brazil Iron Drugs, by Application USD Million (2025-2030)
  • Table 223. Brazil Iron Drugs, by End User USD Million (2025-2030)
  • Table 224. Argentina Iron Drugs, by Type USD Million (2025-2030)
  • Table 225. Argentina Iron Drugs, by Application USD Million (2025-2030)
  • Table 226. Argentina Iron Drugs, by End User USD Million (2025-2030)
  • Table 227. Rest of South America Iron Drugs, by Type USD Million (2025-2030)
  • Table 228. Rest of South America Iron Drugs, by Application USD Million (2025-2030)
  • Table 229. Rest of South America Iron Drugs, by End User USD Million (2025-2030)
  • Table 230. Asia Pacific Iron Drugs, by Country USD Million (2025-2030)
  • Table 231. Asia Pacific Iron Drugs, by Type USD Million (2025-2030)
  • Table 232. Asia Pacific Iron Drugs, by Application USD Million (2025-2030)
  • Table 233. Asia Pacific Iron Drugs, by End User USD Million (2025-2030)
  • Table 234. China Iron Drugs, by Type USD Million (2025-2030)
  • Table 235. China Iron Drugs, by Application USD Million (2025-2030)
  • Table 236. China Iron Drugs, by End User USD Million (2025-2030)
  • Table 237. Japan Iron Drugs, by Type USD Million (2025-2030)
  • Table 238. Japan Iron Drugs, by Application USD Million (2025-2030)
  • Table 239. Japan Iron Drugs, by End User USD Million (2025-2030)
  • Table 240. India Iron Drugs, by Type USD Million (2025-2030)
  • Table 241. India Iron Drugs, by Application USD Million (2025-2030)
  • Table 242. India Iron Drugs, by End User USD Million (2025-2030)
  • Table 243. South Korea Iron Drugs, by Type USD Million (2025-2030)
  • Table 244. South Korea Iron Drugs, by Application USD Million (2025-2030)
  • Table 245. South Korea Iron Drugs, by End User USD Million (2025-2030)
  • Table 246. Taiwan Iron Drugs, by Type USD Million (2025-2030)
  • Table 247. Taiwan Iron Drugs, by Application USD Million (2025-2030)
  • Table 248. Taiwan Iron Drugs, by End User USD Million (2025-2030)
  • Table 249. Australia Iron Drugs, by Type USD Million (2025-2030)
  • Table 250. Australia Iron Drugs, by Application USD Million (2025-2030)
  • Table 251. Australia Iron Drugs, by End User USD Million (2025-2030)
  • Table 252. Rest of Asia-Pacific Iron Drugs, by Type USD Million (2025-2030)
  • Table 253. Rest of Asia-Pacific Iron Drugs, by Application USD Million (2025-2030)
  • Table 254. Rest of Asia-Pacific Iron Drugs, by End User USD Million (2025-2030)
  • Table 255. Europe Iron Drugs, by Country USD Million (2025-2030)
  • Table 256. Europe Iron Drugs, by Type USD Million (2025-2030)
  • Table 257. Europe Iron Drugs, by Application USD Million (2025-2030)
  • Table 258. Europe Iron Drugs, by End User USD Million (2025-2030)
  • Table 259. Germany Iron Drugs, by Type USD Million (2025-2030)
  • Table 260. Germany Iron Drugs, by Application USD Million (2025-2030)
  • Table 261. Germany Iron Drugs, by End User USD Million (2025-2030)
  • Table 262. France Iron Drugs, by Type USD Million (2025-2030)
  • Table 263. France Iron Drugs, by Application USD Million (2025-2030)
  • Table 264. France Iron Drugs, by End User USD Million (2025-2030)
  • Table 265. Italy Iron Drugs, by Type USD Million (2025-2030)
  • Table 266. Italy Iron Drugs, by Application USD Million (2025-2030)
  • Table 267. Italy Iron Drugs, by End User USD Million (2025-2030)
  • Table 268. United Kingdom Iron Drugs, by Type USD Million (2025-2030)
  • Table 269. United Kingdom Iron Drugs, by Application USD Million (2025-2030)
  • Table 270. United Kingdom Iron Drugs, by End User USD Million (2025-2030)
  • Table 271. Netherlands Iron Drugs, by Type USD Million (2025-2030)
  • Table 272. Netherlands Iron Drugs, by Application USD Million (2025-2030)
  • Table 273. Netherlands Iron Drugs, by End User USD Million (2025-2030)
  • Table 274. Rest of Europe Iron Drugs, by Type USD Million (2025-2030)
  • Table 275. Rest of Europe Iron Drugs, by Application USD Million (2025-2030)
  • Table 276. Rest of Europe Iron Drugs, by End User USD Million (2025-2030)
  • Table 277. MEA Iron Drugs, by Country USD Million (2025-2030)
  • Table 278. MEA Iron Drugs, by Type USD Million (2025-2030)
  • Table 279. MEA Iron Drugs, by Application USD Million (2025-2030)
  • Table 280. MEA Iron Drugs, by End User USD Million (2025-2030)
  • Table 281. Middle East Iron Drugs, by Type USD Million (2025-2030)
  • Table 282. Middle East Iron Drugs, by Application USD Million (2025-2030)
  • Table 283. Middle East Iron Drugs, by End User USD Million (2025-2030)
  • Table 284. Africa Iron Drugs, by Type USD Million (2025-2030)
  • Table 285. Africa Iron Drugs, by Application USD Million (2025-2030)
  • Table 286. Africa Iron Drugs, by End User USD Million (2025-2030)
  • Table 287. North America Iron Drugs, by Country USD Million (2025-2030)
  • Table 288. North America Iron Drugs, by Type USD Million (2025-2030)
  • Table 289. North America Iron Drugs, by Application USD Million (2025-2030)
  • Table 290. North America Iron Drugs, by End User USD Million (2025-2030)
  • Table 291. United States Iron Drugs, by Type USD Million (2025-2030)
  • Table 292. United States Iron Drugs, by Application USD Million (2025-2030)
  • Table 293. United States Iron Drugs, by End User USD Million (2025-2030)
  • Table 294. Canada Iron Drugs, by Type USD Million (2025-2030)
  • Table 295. Canada Iron Drugs, by Application USD Million (2025-2030)
  • Table 296. Canada Iron Drugs, by End User USD Million (2025-2030)
  • Table 297. Mexico Iron Drugs, by Type USD Million (2025-2030)
  • Table 298. Mexico Iron Drugs, by Application USD Million (2025-2030)
  • Table 299. Mexico Iron Drugs, by End User USD Million (2025-2030)
  • Table 300. Iron Drugs Sales: by Type(K Units)
  • Table 301. Iron Drugs Sales Iron Dextran , by Region K Units (2025-2030)
  • Table 302. Iron Drugs Sales Iron Sucrose , by Region K Units (2025-2030)
  • Table 303. Iron Drugs Sales Ferric Carboxymaltose , by Region K Units (2025-2030)
  • Table 304. Iron Drugs Sales Others , by Region K Units (2025-2030)
  • Table 305. Iron Drugs Sales: by Application(K Units)
  • Table 306. Iron Drugs Sales Chronic Kidney Disease , by Region K Units (2025-2030)
  • Table 307. Iron Drugs Sales Inflammatory Bowel Disease , by Region K Units (2025-2030)
  • Table 308. Iron Drugs Sales Cancer Diseases , by Region K Units (2025-2030)
  • Table 309. Iron Drugs Sales Others , by Region K Units (2025-2030)
  • Table 310. Iron Drugs Sales: by End User(K Units)
  • Table 311. Iron Drugs Sales Hospital , by Region K Units (2025-2030)
  • Table 312. Iron Drugs Sales Clinics , by Region K Units (2025-2030)
  • Table 313. Iron Drugs Sales Others , by Region K Units (2025-2030)
  • Table 314. South America Iron Drugs Sales, by Country K Units (2025-2030)
  • Table 315. South America Iron Drugs Sales, by Type K Units (2025-2030)
  • Table 316. South America Iron Drugs Sales, by Application K Units (2025-2030)
  • Table 317. South America Iron Drugs Sales, by End User K Units (2025-2030)
  • Table 318. Brazil Iron Drugs Sales, by Type K Units (2025-2030)
  • Table 319. Brazil Iron Drugs Sales, by Application K Units (2025-2030)
  • Table 320. Brazil Iron Drugs Sales, by End User K Units (2025-2030)
  • Table 321. Argentina Iron Drugs Sales, by Type K Units (2025-2030)
  • Table 322. Argentina Iron Drugs Sales, by Application K Units (2025-2030)
  • Table 323. Argentina Iron Drugs Sales, by End User K Units (2025-2030)
  • Table 324. Rest of South America Iron Drugs Sales, by Type K Units (2025-2030)
  • Table 325. Rest of South America Iron Drugs Sales, by Application K Units (2025-2030)
  • Table 326. Rest of South America Iron Drugs Sales, by End User K Units (2025-2030)
  • Table 327. Asia Pacific Iron Drugs Sales, by Country K Units (2025-2030)
  • Table 328. Asia Pacific Iron Drugs Sales, by Type K Units (2025-2030)
  • Table 329. Asia Pacific Iron Drugs Sales, by Application K Units (2025-2030)
  • Table 330. Asia Pacific Iron Drugs Sales, by End User K Units (2025-2030)
  • Table 331. China Iron Drugs Sales, by Type K Units (2025-2030)
  • Table 332. China Iron Drugs Sales, by Application K Units (2025-2030)
  • Table 333. China Iron Drugs Sales, by End User K Units (2025-2030)
  • Table 334. Japan Iron Drugs Sales, by Type K Units (2025-2030)
  • Table 335. Japan Iron Drugs Sales, by Application K Units (2025-2030)
  • Table 336. Japan Iron Drugs Sales, by End User K Units (2025-2030)
  • Table 337. India Iron Drugs Sales, by Type K Units (2025-2030)
  • Table 338. India Iron Drugs Sales, by Application K Units (2025-2030)
  • Table 339. India Iron Drugs Sales, by End User K Units (2025-2030)
  • Table 340. South Korea Iron Drugs Sales, by Type K Units (2025-2030)
  • Table 341. South Korea Iron Drugs Sales, by Application K Units (2025-2030)
  • Table 342. South Korea Iron Drugs Sales, by End User K Units (2025-2030)
  • Table 343. Taiwan Iron Drugs Sales, by Type K Units (2025-2030)
  • Table 344. Taiwan Iron Drugs Sales, by Application K Units (2025-2030)
  • Table 345. Taiwan Iron Drugs Sales, by End User K Units (2025-2030)
  • Table 346. Australia Iron Drugs Sales, by Type K Units (2025-2030)
  • Table 347. Australia Iron Drugs Sales, by Application K Units (2025-2030)
  • Table 348. Australia Iron Drugs Sales, by End User K Units (2025-2030)
  • Table 349. Rest of Asia-Pacific Iron Drugs Sales, by Type K Units (2025-2030)
  • Table 350. Rest of Asia-Pacific Iron Drugs Sales, by Application K Units (2025-2030)
  • Table 351. Rest of Asia-Pacific Iron Drugs Sales, by End User K Units (2025-2030)
  • Table 352. Europe Iron Drugs Sales, by Country K Units (2025-2030)
  • Table 353. Europe Iron Drugs Sales, by Type K Units (2025-2030)
  • Table 354. Europe Iron Drugs Sales, by Application K Units (2025-2030)
  • Table 355. Europe Iron Drugs Sales, by End User K Units (2025-2030)
  • Table 356. Germany Iron Drugs Sales, by Type K Units (2025-2030)
  • Table 357. Germany Iron Drugs Sales, by Application K Units (2025-2030)
  • Table 358. Germany Iron Drugs Sales, by End User K Units (2025-2030)
  • Table 359. France Iron Drugs Sales, by Type K Units (2025-2030)
  • Table 360. France Iron Drugs Sales, by Application K Units (2025-2030)
  • Table 361. France Iron Drugs Sales, by End User K Units (2025-2030)
  • Table 362. Italy Iron Drugs Sales, by Type K Units (2025-2030)
  • Table 363. Italy Iron Drugs Sales, by Application K Units (2025-2030)
  • Table 364. Italy Iron Drugs Sales, by End User K Units (2025-2030)
  • Table 365. United Kingdom Iron Drugs Sales, by Type K Units (2025-2030)
  • Table 366. United Kingdom Iron Drugs Sales, by Application K Units (2025-2030)
  • Table 367. United Kingdom Iron Drugs Sales, by End User K Units (2025-2030)
  • Table 368. Netherlands Iron Drugs Sales, by Type K Units (2025-2030)
  • Table 369. Netherlands Iron Drugs Sales, by Application K Units (2025-2030)
  • Table 370. Netherlands Iron Drugs Sales, by End User K Units (2025-2030)
  • Table 371. Rest of Europe Iron Drugs Sales, by Type K Units (2025-2030)
  • Table 372. Rest of Europe Iron Drugs Sales, by Application K Units (2025-2030)
  • Table 373. Rest of Europe Iron Drugs Sales, by End User K Units (2025-2030)
  • Table 374. MEA Iron Drugs Sales, by Country K Units (2025-2030)
  • Table 375. MEA Iron Drugs Sales, by Type K Units (2025-2030)
  • Table 376. MEA Iron Drugs Sales, by Application K Units (2025-2030)
  • Table 377. MEA Iron Drugs Sales, by End User K Units (2025-2030)
  • Table 378. Middle East Iron Drugs Sales, by Type K Units (2025-2030)
  • Table 379. Middle East Iron Drugs Sales, by Application K Units (2025-2030)
  • Table 380. Middle East Iron Drugs Sales, by End User K Units (2025-2030)
  • Table 381. Africa Iron Drugs Sales, by Type K Units (2025-2030)
  • Table 382. Africa Iron Drugs Sales, by Application K Units (2025-2030)
  • Table 383. Africa Iron Drugs Sales, by End User K Units (2025-2030)
  • Table 384. North America Iron Drugs Sales, by Country K Units (2025-2030)
  • Table 385. North America Iron Drugs Sales, by Type K Units (2025-2030)
  • Table 386. North America Iron Drugs Sales, by Application K Units (2025-2030)
  • Table 387. North America Iron Drugs Sales, by End User K Units (2025-2030)
  • Table 388. United States Iron Drugs Sales, by Type K Units (2025-2030)
  • Table 389. United States Iron Drugs Sales, by Application K Units (2025-2030)
  • Table 390. United States Iron Drugs Sales, by End User K Units (2025-2030)
  • Table 391. Canada Iron Drugs Sales, by Type K Units (2025-2030)
  • Table 392. Canada Iron Drugs Sales, by Application K Units (2025-2030)
  • Table 393. Canada Iron Drugs Sales, by End User K Units (2025-2030)
  • Table 394. Mexico Iron Drugs Sales, by Type K Units (2025-2030)
  • Table 395. Mexico Iron Drugs Sales, by Application K Units (2025-2030)
  • Table 396. Mexico Iron Drugs Sales, by End User K Units (2025-2030)
  • Table 397. Iron Drugs: by Type(USD/Units)
  • Table 398. Research Programs/Design for This Report
  • Table 399. Key Data Information from Secondary Sources
  • Table 400. Key Data Information from Primary Sources
List of Figures
  • Figure 1. Porters Five Forces
  • Figure 2. Supply/Value Chain
  • Figure 3. PESTEL analysis
  • Figure 4. Europe Iron Drugs: by Type USD Million (2018-2023)
  • Figure 5. Europe Iron Drugs: by Application USD Million (2018-2023)
  • Figure 6. Europe Iron Drugs: by End User USD Million (2018-2023)
  • Figure 7. South America Iron Drugs Share (%), by Country
  • Figure 8. Asia Pacific Iron Drugs Share (%), by Country
  • Figure 9. Europe Iron Drugs Share (%), by Country
  • Figure 10. MEA Iron Drugs Share (%), by Country
  • Figure 11. North America Iron Drugs Share (%), by Country
  • Figure 12. Europe Iron Drugs: by Type K Units (2018-2023)
  • Figure 13. Europe Iron Drugs: by Application K Units (2018-2023)
  • Figure 14. Europe Iron Drugs: by End User K Units (2018-2023)
  • Figure 15. South America Iron Drugs Share (%), by Country
  • Figure 16. Asia Pacific Iron Drugs Share (%), by Country
  • Figure 17. Europe Iron Drugs Share (%), by Country
  • Figure 18. MEA Iron Drugs Share (%), by Country
  • Figure 19. North America Iron Drugs Share (%), by Country
  • Figure 20. Europe Iron Drugs: by Type USD/Units (2018-2023)
  • Figure 21. Europe Iron Drugs share by Players 2023 (%)
  • Figure 22. Europe Iron Drugs share by Players (Top 3) 2023(%)
  • Figure 23. BCG Matrix for key Companies
  • Figure 24. Allergan, Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 25. Allergan, Inc. (United States) Revenue: by Geography 2023
  • Figure 26. AMAG Pharmaceuticals, Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 27. AMAG Pharmaceuticals, Inc. (United States) Revenue: by Geography 2023
  • Figure 28. Daiichi Sankyo (Japan) Revenue, Net Income and Gross profit
  • Figure 29. Daiichi Sankyo (Japan) Revenue: by Geography 2023
  • Figure 30. Pharmacosmos (Denmark) Revenue, Net Income and Gross profit
  • Figure 31. Pharmacosmos (Denmark) Revenue: by Geography 2023
  • Figure 32. Vifor Pharma (Switzerland) Revenue, Net Income and Gross profit
  • Figure 33. Vifor Pharma (Switzerland) Revenue: by Geography 2023
  • Figure 34. Galenica (Switzerland) Revenue, Net Income and Gross profit
  • Figure 35. Galenica (Switzerland) Revenue: by Geography 2023
  • Figure 36. Nippon Shinyaku (Japan) Revenue, Net Income and Gross profit
  • Figure 37. Nippon Shinyaku (Japan) Revenue: by Geography 2023
  • Figure 38. Europe Iron Drugs: by Type USD Million (2025-2030)
  • Figure 39. Europe Iron Drugs: by Application USD Million (2025-2030)
  • Figure 40. Europe Iron Drugs: by End User USD Million (2025-2030)
  • Figure 41. South America Iron Drugs Share (%), by Country
  • Figure 42. Asia Pacific Iron Drugs Share (%), by Country
  • Figure 43. Europe Iron Drugs Share (%), by Country
  • Figure 44. MEA Iron Drugs Share (%), by Country
  • Figure 45. North America Iron Drugs Share (%), by Country
  • Figure 46. Europe Iron Drugs: by Type K Units (2025-2030)
  • Figure 47. Europe Iron Drugs: by Application K Units (2025-2030)
  • Figure 48. Europe Iron Drugs: by End User K Units (2025-2030)
  • Figure 49. South America Iron Drugs Share (%), by Country
  • Figure 50. Asia Pacific Iron Drugs Share (%), by Country
  • Figure 51. Europe Iron Drugs Share (%), by Country
  • Figure 52. MEA Iron Drugs Share (%), by Country
  • Figure 53. North America Iron Drugs Share (%), by Country
  • Figure 54. Europe Iron Drugs: by Type USD/Units (2025-2030)
List of companies from research coverage that are profiled in the study
  • Allergan, Inc. (United States)
  • AMAG Pharmaceuticals, Inc. (United States)
  • Daiichi Sankyo (Japan)
  • Pharmacosmos (Denmark)
  • Vifor Pharma (Switzerland)
  • Galenica (Switzerland)
  • Nippon Shinyaku (Japan)
Additional players considered in the study are as follows:
Sanofi S.A. (France) , Shield Therapeutics plc (United States) , Wanbang Biopharmaceutical (China)
Select User Access Type

Key Highlights of Report


Mar 2024 239 Pages 78 Tables Base Year: 2023 Coverage: 15+ Companies; 18 Countries

Request Sample Pages

Budget constraints? Get in touch with us for special pricing


Check Discount Now
Global Iron Drugs Quantitative research analysis
Global Iron Drugs Qualitative Industry Analysis
DOWNLOAD SAMPLE PDF

Talk to Our Experts

Want to Customize Study?


"We employ Market statistics, Industry benchmarking, Patent analysis, and Technological Insights to derive requirements and provide customize scope of work."

Make an Enquiry Now

Frequently Asked Questions (FAQ):

The key segments that are playing vital role in Iron Drugs Market are by type [Iron Dextran, Iron Sucrose, Ferric Carboxymaltose and Others], by end use application [Chronic Kidney Disease, Inflammatory Bowel Disease, Cancer Diseases and Others].
The Iron Drugs Market is gaining popularity and expected to see strong valuation by 2030.
  • Growing Prevalence of Chronic Kidney Disease
  • increasing Number of Patients Undergoing Dialysis
  • Rising Investment by Governments and Private Companies in Biotechnology and Biopharmaceutical Industry

Know More About Global Iron Drugs Report?

Have a Query? Click Here

Other Related Reports

Gravid Treatment Comprehensive Study by Type (Topical Products, Lasers, Microdermabrasion, Others), Application (Hospitals, Clinics, Specialty Dermatology Centres, Home-use, Others) Players and Regio...
$ 3500
Glaucoma Eye Drops Comprehensive Study by Type (Prostaglandin Analogs, Prostaglandin Analogs, Alpha Agonists, Carbonic Anhydrase Inhibitors (Cais), Rho Khinase Inhibitors, Combined Medications, Other...
$ 3650
Photosensitizer Drug Comprehensive Study by Type (Porphyrin Derivatives (PD) (Hematoporphyrin Derivative (HpD), Benzoporphyrin Derivative (BPD), Texaphyrins, Others), Aminolevulinic acid (ALA), Chlor...
$ 3750
Oral Antiseptics Comprehensive Study by Type (Chlorhexidine Gluconate, Essential Oils, Methyl Salicylate, Povidone-Iodine, Hydrogen Peroxide, Cetylpyridinium Chloride), Application (Dental Care, Oral...
$ 3650
Respiratory Drugs Comprehensive Study by Type (Antiasthmatic combinations, Antihistamines, Antitussives, Bronchodilators, Others), Disease Type (Asthma, COPD, Allergic rhinitis, Cystic fibrosis, Idio...
$ 3650
Pasireotide Comprehensive Study by Form (Liquid Solution, Powder), Dosage (0.3mg/ml, 0.6mg/ml, 0.9mg/ml), End User (Hospital, Pharmacy) Players and Region - Americas Market Outlook to 2026
$ 3500